Annion Pharma Consulting promotes the following course. 

Preclinical safety assessment of a potential drug represents an essential part of its development process. The low success rate of development programmes has caused an intensification and expansion of the field of safety science, towards a much more integrated view of safety from early discovery to post-marketing safety monitoring. This first course will allow to gain a deeper insight in: regulatory requirements for studies used in preclinical safety assessment; preclinical testing of candidate drugs to demonstrate potential harmful effects; assessment of risk/benefit profiling of drugs; integration of safety aspects in the overall risk assessment for selection of drug candidates; calculation of the maximum recommended starting dose in FIH trial based on the preclinical studies and strategies for preclinical development.

Full programme

For: This course is designed for drug R&D professionals who wish to develop their skills and knowledge in preclinical safety. The training panel will join leading scientists in the pharmaceutical industry and preclinical CRO and consultancies.

Language: English

Registration:

• General: 725€ (+21% IVA)
• 15% discount for CataloniaBio & HealthTech members. Ask for your promotional code to imma.esposito@cataloniabioht.org.
• 10% discount for more than 2 delegates

Includes coffee break, lunch and documentation.